19 November 2018
Verily from Alphabet, the parent company of Google introduced its health watch in 2017. It is particularly aimed at gathering insights on medical conditions like MS and Parkinson’s.
Now Verily has achieved the FDA clearance for its electrocardiogram (ECG) technology. This means the watch will offer various future indications and the agency has designated the watch as a Class II medical device. Verily while announcing this major milestone stated that its area of focus for Study Watch has been cardiovascular health because it has been killing the lives. According to the American Heart Association (AHA), most cardiovascular events are preventable so mobile health sector must enhance so to eradicate this major problem.
According to Engadget, doctors may prescribe the device to individuals as part of their clinical care while the research trials are going on.
The FDA-cleared Study Watch intends to record, store, transfer, and display single-channel ECG rhythms and is indicated for use by healthcare professionals, adult patients with known or suspected heart conditions
“Receiving this clearance showcases our commitment to the high standards of the FDA for safety and effectiveness and will help us advance the application of Study Watch in various disease areas and future indications.”